DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Brian Gastman, Omid Hamid, Philippa Gail Corrie, Bartosz Chmielowski, Sajeve Samuel Thomas, Gregory A. Daniels, Evidio Domingo-Musibay, Donald P. Lawrence, Eric D. Whitman, Geoffrey Thomas Gibney, Anthony J. Olszanski, Yizhou Jiang, Audrey Kennedy, Jeff Aycock, Paul B. Robbins, John Brian Le Gall, Zachary Roberts, Robert E. Hawkins, Amod Sarnaik
Institutions: Cleveland Clinic Lerner College of Medicine, Angeles Clinic and Research Institute, Addenbrooke's Hospital, University of California, Los Angeles, Orlando Health, Moores Cancer Center, Masonic Cancer Center, Harvard University, Massachusetts General Hospital, Atlantic Health System, MedStar Georgetown University Hospital, Fox Chase Cancer Center, Moffitt Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286298145